The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Andreas Pfützner

IKFE-Institute for Clinical Research and Development

Mainz

Germany

[email]@ikfe.de

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • IKFE-Institute for Clinical Research and Development, Mainz, Germany. 2003 - 2012
  • University of Applied Sciences, Rheinbach, Germany. 2005 - 2006
  • Institut für Klinische Forschung und Entwicklung IKFE, Institute for Clinical Research and Development, Parcusstr. 8, D-55116 Mainz, Germany. 2006
  • MannKind Biopharmaceuticals, 1 Casper Street, Danbury, USA. 2003
  • Institut für klinische Forschung und Entwicklung, Mainze. 2002
  • Pharmaceutical Discovery Corporation, A MannKind Company, Danbury, Connecticut, USA. 2002
  • Endocrine Research Laboratory ELAB, University Hospital Mainz, Germany. 2000

References

  1. Comparison of patient preference for two insulin injection pen devices in relation to patient dexterity skills. Pfützner, A., Schipper, C., Niemeyer, M., Qvist, M., Löffler, A., Forst, T., Musholt, P.B. J. Diabetes. Sci. Technol (2012) [Pubmed]
  2. High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone. Pfützner, A., Schöndorf, T., Hanefeld, M., Forst, T. J. Diabetes. Sci. Technol (2010) [Pubmed]
  3. Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study. Pfützner, A., Derwahl, M., Jacob, S., Hohberg, C., Blümner, E., Lehmann, U., Fuchs, W., Forst, T. Diabetes Technol. Ther. (2010) [Pubmed]
  4. Intensification with prandial insulin. Pfützner, A., Forst, T. Int. J. Clin. Pract. Suppl (2009) [Pubmed]
  5. Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study. Pfützner, A., Efstrathios, K., Löbig, M., Armbruster, F.P., Hanefeld, M., Forst, T. Clin. Lab. (2009) [Pubmed]
  6. FlexPen for the delivery of insulin: accuracy, injection force and patient preference. Pfützner, A. Expert. Rev. Med. Devices (2009) [Pubmed]
  7. Differences in the dose accuracy of insulin pens. Hänel, H., Weise, A., Sun, W., Pfützner, J.W., Thomé, N., Pfützner, A. J. Diabetes. Sci. Technol (2008) [Pubmed]
  8. Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease. Pfützner, A., Marx, N., Walcher, D., Löbig, M., Seidel, D., Forst, T. Clin. Lab. (2008) [Pubmed]
  9. A biomarker concept for assessment of insulin resistance, beta-cell function and chronic systemic inflammation in type 2 diabetes mellitus. Pfützner, A., Weber, M.M., Forst, T. Clin. Lab. (2008) [Pubmed]
  10. Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects. Pfützner, A., Weber, M.M., Forst, T. Expert. Opin. Pharmacother (2007) [Pubmed]
  11. Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination. Pfützner, A., Wilhelm, B., Forst, T. Vasc. Health. Risk. Manag (2007) [Pubmed]
  12. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Pfützner, A., Schöndorf, T., Seidel, D., Winkler, K., Matthaei, S., Hamann, A., Forst, T. Metab. Clin. Exp. (2006) [Pubmed]
  13. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Pfützner, A., Forst, T. Diabetes Technol. Ther. (2006) [Pubmed]
  14. Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality. Pfützner, A., Forst, T. Expert. Opin. Pharmacother (2006) [Pubmed]
  15. Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus. Pfützner, A., Standl, E., Strotmann, H.J., Schulze, J., Hohberg, C., Lübben, G., Pahler, S., Schöndorf, T., Forst, T. Clin. Chem. Lab. Med. (2006) [Pubmed]
  16. The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus. Pfützner, A., Lorra, B., Abdollahnia, M.R., Kann, P.H., Mathieu, D., Pehnert, C., Oligschleger, C., Kaiser, M., Forst, T. Diabetes Technol. Ther. (2006) [Pubmed]
  17. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Pfützner, A., Schneider, C.A., Forst, T. Expert. Rev. Cardiovasc. Ther (2006) [Pubmed]
  18. IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study design. Pfützner, A., Standl, E., Hohberg, C., Konrad, T., Strotmann, H.J., Lübben, G., Langenfeld, M.R., Schulze, J., Forst, T. Diabetes Technol. Ther. (2005) [Pubmed]
  19. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. Pfützner, A., Marx, N., Lübben, G., Langenfeld, M., Walcher, D., Konrad, T., Forst, T. J. Am. Coll. Cardiol. (2005) [Pubmed]
  20. Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin. Pfützner, A., Pfützner, A.H., Kann, P.H., Stute, R., Löbig, M., Yang, J.W., Mistry, J., Forst, T. Clin. Lab. (2005) [Pubmed]
  21. Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Pfützner, A., Hohberg, C., Lübben, G., Pahler, S., Pfützner, A.H., Kann, P., Forst, T. Horm. Metab. Res. (2005) [Pubmed]
  22. Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Pfützner, A., Forst, T. Expert. Opin. Drug. Deliv (2005) [Pubmed]
  23. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Pfützner, A., Kunt, T., Hohberg, C., Mondok, A., Pahler, S., Konrad, T., Lübben, G., Forst, T. Diabetes. Care (2004) [Pubmed]
  24. Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Pfützner, A., Pfützner, A.H., Larbig, M., Forst, T. Diabetes Technol. Ther. (2004) [Pubmed]
  25. Impact of posture and fixation technique on impedance spectroscopy used for continuous and noninvasive glucose monitoring. Pfützner, A., Caduff, A., Larbig, M., Schrepfer, T., Forst, T. Diabetes Technol. Ther. (2004) [Pubmed]
  26. Pilot study with technosphere/PTH(1-34)--a new approach for effective pulmonary delivery of parathyroid hormone (1-34). Pfützner, A., Flacke, F., Pohl, R., Linkie, D., Engelbach, M., Woods, R., Forst, T., Beyer, J., Steiner, S.S. Horm. Metab. Res. (2003) [Pubmed]
  27. Clinical and laboratory evaluation of specific chemiluminescence assays for intact and total proinsulin. Pfützner, A., Kunt, T., Langenfeld, M., Löbig, M., Knesovic, M., Forst, T. Clin. Chem. Lab. Med. (2003) [Pubmed]
  28. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Pfützner, A., Langenfeld, M., Kunt, T., Löbig, M., Forst, T. Clin. Lab. (2003) [Pubmed]
  29. Evaluation of a new fully automated one-step C-peptide chemiluminescence assay (LIAISON C-Peptid). Pfützner, A., Löbig, M., Fortunato, A., Forst, T. Clin. Lab. (2003) [Pubmed]
  30. Cross-sectional investigation on the accuracy of alternate site glucose testing using the Soft-Sense glucose meter. Pfützner, A., Hermanns, N., Schröder, S., Wegenstein, M., Larbig, M., Mondok, A., Forst, T., Haak, T. Swiss. Med. Wkly (2002) [Pubmed]
  31. Technosphere/Insulin--a new approach for effective delivery of human insulin via the pulmonary route. Pfützner, A., Mann, A.E., Steiner, S.S. Diabetes Technol. Ther. (2002) [Pubmed]
  32. Comparison of immunoassays for the detection of anti-GAD65 autoantibodies in patients with diabetes mellitus. Pfützner, A., Harzer, O., Kunt, T., Forst, T., Abdollahnia, N., Löbig, M., Krauss, H., Engelbach, M., Kann, P., Beyer, J. Clin. Lab. (2000) [Pubmed]
 
WikiGenes - Universities